GeneDx Holdings Corp
For the period ended Dec 31, 2024. Filed Feb 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 20, 2025
WGS$54.83-16.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net loss | $(52,286) | $(175,767) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 21,953 | 33,734 |
| Stock-based compensation expense | 9,138 | (326) |
| Change in fair value of warrants and contingent liabilities | 13,370 | (1,170) |
| Deferred tax benefit | (343) | (926) |
| Provision for excess and obsolete inventory | 180 | 3,913 |
| Change in third party payor reserves | 607 | (9,745) |
| Gain on sale of assets | — | (1,677) |
| Gain on debt forgiveness | — | (2,750) |
| Impairment loss | — | 10,402 |
| Other | 3,630 | 2,406 |
| Change in operating assets and liabilities: | ||
| Accounts receivable | (5,421) | 10,263 |
| Inventory | (2,585) | 975 |
| Accounts payable and accrued expenses | (20,461) | (46,953) |
| Other assets and liabilities | 3,722 | (2,526) |
| Net cash used in operating activities | (28,496) | (180,147) |
| Investing activities | ||
| Proceeds from maturities of marketable securities | 41,060 | 17,765 |
| Purchases of marketable securities | (66,302) | (47,670) |
| Purchases of property and equipment | (5,491) | (5,250) |
| Proceeds from sales of marketable securities | 601 | — |
| Consideration on escrow paid for Legacy GeneDx acquisition | — | (12,144) |
| Proceeds from sales of assets | — | 4,034 |
| Development of internal-use software assets | — | (461) |
| Net cash used in investing activities | (30,132) | (43,726) |
| Financing activities | ||
| Proceeds from offerings, net of issuance costs | 46,496 | 143,002 |
| Exercise of stock options | 394 | 285 |
| Issuance of stock pursuant to employee stock purchase plan | 497 | — |
| Long-term debt principal payments | (497) | (2,000) |
| Finance lease payoff and principal payments | (2,728) | (3,598) |
| Proceeds from long-term debt | — | 48,549 |
| Net cash provided by financing activities | 44,162 | 186,238 |
| Net decrease in cash, cash equivalents and restricted cash | (14,466) | (37,635) |
| Cash, cash equivalents and restricted cash, at beginning of year | 100,668 | 138,303 |
| Cash, cash equivalents and restricted cash, at end of year | $86,202 | $100,668 |
| Supplemental disclosures of cash flow information | ||
| Stock consideration paid pursuant to exercise of Perceptive warrant | $12,586 | $— |
| Cash paid for interest | $6,677 | $3,041 |
| Purchases of property and equipment in accounts payable and accrued expenses | $2,597 | $134 |
| Cash paid for taxes | $1,167 | $1,465 |
| Assets acquired under capital leases obligations | $689 | $— |
| Issuance of common stock for first Milestone Payment | $— | $6,692 |
| Lease liability from obtaining right-of-use asset | $— | $637 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.